Technology | September 11, 2014

iCAD to Showcase its Electronic Brachytherapy Solutions and Services at ASTRO

iCAD's Xoft Axxent electronic brachytherapy (eBx) system

September 11, 2014 — iCAD Inc. will debut the company's latest technological advances and present updates on clinical data and patient outcomes using the Xoft Axxent electronic brachytherapy (eBx) system in the treatment of cancer during the upcoming American Society for Therapeutic Radiology and Oncology (ASTRO) meeting, Sept. 14-17.

Throughout the meeting iCAD will also showcase its expanded and comprehensive software and service offerings following the recent acquisitions of DermEbx and Radion, and will highlight innovations in technology with live product demonstrations of its Xoft system at booth #1938.

"This is a very exciting year for iCAD as we have significantly expanded our position as the industry's leading comprehensive solution provider in eBx. We look forward to outlining the elements of our new solutions and services and to giving customers a hands-on experience with our recent advances to the technology platforms, including the debut of our Axxent SPX controller, the latest extension of the Xoft system product line," said Ken Ferry, president and CEO of iCAD. "With our progress this year, iCAD is uniquely positioned to provide significant technology and service advantages to our valued customers and their patients."

"We continue to be encouraged by the positive data presented on the Xoft system for the treatment of non-melanoma skin cancer, as it further demonstrates the system's distinct clinical and cosmetic advantages," added Ferry.

During ASTRO iCAD will debut the new Axxent SPX controller, the latest extension of the Axxent product line. The Axxent SPX controller features a streamlined design to support enhanced mobility and flexibility for delivery of electronic brachytherapy treatment in a wider range of healthcare settings, including smaller treatment rooms. The controller also features new software and an enhanced barcode scanning function that offers significant workflow benefits and improved technology support for HIPAA compliance. These features are also now available on the multiplatform Axxent MPX controller, which remains commercially available as the company's platform product approved for use in all indications including breast intraoperative radiation therapy (IORT), breast accelerated partial breast irradiation (APBI), skin, endometrial and cervical cancer treatments.

"Electronic brachytherapy allows radiation oncologists to expand the reach of HDR [high-dose-rate] brachytherapy beyond conventional shielded vaults. It inherently offers safety for patients and personnel, target flexibility for challenging anatomic areas and fine radiation dose control. The new streamlined design may be easier to integrate into smaller spaces in many clinical facilities," said Rakesh Patel, M.D., medical director at the Targeted Radiation Institutes in the East and South Bay Areas in California.

For more information:,

Related Content

RayCare Oncology Information System Being Shown at ASTRO 2017
News | Radiation Therapy | September 20, 2017
RaySearch will be exhibiting its next-generation oncology information system (OIS) RayCare, among other highlights, at...
ProCure Proton Therapy Center New Jersey Celebrates Five-Year Cancer-Free Milestone for Prostate Cancer Patients
News | Proton Therapy | September 20, 2017
ProCure Proton Therapy Center in Somerset, N.J., recently celebrated the five-year cancer-free milestone for the first...
Varian to Showcase Latest Radiation Therapy Technologies and Software at ASTRO 2017
News | Radiation Therapy | September 19, 2017
Varian Medical Systems announced it will be demonstrating its new Halcyon platform and HyperArc high-definition...
Elekta to Highlight MOSAIQ Oncology Analytics at ASTRO Annual Meeting
News | Radiation Therapy | September 19, 2017
September 19, 2017 — Elekta will highlight its Mosaiq Oncology...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Clinical Trials and Cutting-Edge Radiation Oncology Research to Be Featured at ASTRO 2017
News | Radiation Therapy | September 14, 2017
The program for the 2017 Annual Meeting of the American Society for Radiation Oncology (ASTRO), Sept. 24-27 in San...
Provision Healthcare Joins RayCare Clinical Partners
News | Oncology Information Management Systems (OIMS) | September 11, 2017
Provision, located in Knoxville, Tenn., is the latest to partner with RaySearch Laboratories on the development of its...
U.K.'s NICE Supports Use of Hydrogel Spacer in Prostate Cancer Treatement
News | Patient Positioning Radiation Therapy | September 08, 2017
Augmenix Inc. announced that the National Institute for Health and Care Excellence (NICE) in the U.K. has issued...
Sponsored Content | Videos | Radiation Therapy | September 08, 2017
The new Visicoil MR is a helically-wound, flexible linear fiducial marker.
FDG-PET/CT Predicts Melanoma Patients' Response to Immune Checkpoint Inhibitor Therapy
News | PET-CT | September 07, 2017
September 7, 2017 — Advanced melanoma has a poor prognosis, but immune checkpoint inhibitor therapy can be effective
Overlay Init